DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20190011

Cd4 count at the time of presentation in newly diagnosed HIV patients in a tertiary care hospital in south India: implications for the programme

Krishna Rajesh Kilaru, Likhita Punuru, Venkateswara Rao Garimella, Sindhu Kande

Abstract


Background: Lower CD4 count at initiation of antiretroviral therapy (ART) can have a significant negative impact on subsequent disease progression and mortality among HIV patients. Hence, author assessed the status of the CD4 count at the time of diagnosis and factors associated with lower CD4 count among newly diagnosed HIV cases.

Methods: A prospective observational study was conducted in a single integrated counseling and testing center, affiliated with a Medical College and Hospital, Andhra Pradesh. All newly diagnosed HIV cases in the setting between January to December 2017 were included. The CD4 count was assessed as per national guidelines for enumeration of CD4 2015.

Results: The final analysis included 125 participants. The mean CD4 count at diagnosis was 276.51±228.37. Only 19 (15.20%) people had CD4 count >500, 47 (37.60%) had between 200-500 and 59 (47.20%) had CD4 count <200. Only 20% had appropriate knowledge of treatment. Among the study population, 43 (34.70%) had symptomatic conditions attributed to HIV infection, 44 (35.50%) participants had an AIDS-defining illness at the time of diagnosis. Only 3 (2.40%) had voluntary counseling and testing. Even though male gender, poor educational status, having more sexual partners, poor knowledge related to HIV diagnosis and treatment was associated with higher odds of low CD4 count (<200), none of the associations were statistically significant.

Conclusions: The mean CD4 count was low and almost half of newly diagnosed cases had low CD4 count (<200) at the time of diagnosis. There is a strong need to intensify the efforts to fill the gaps in the screening for the early diagnosis to maximize the benefits of HAART and to stop the spread of the infection.


Keywords


CD4 count, Highly Active Anti-Retroviral Therapy (HAART), Newly diagnosed HIV

Full Text:

PDF

References


India. UNAIDS, 2018. Available at: http://www.unaids.org/en/regionscountries/countries/india. Accessed 24 April 2018.

National AIDS Control Organisation Ministry of Health and Family Welfare Government of India, National Strategic Plan for HIV/AIDS and STI, 2017-2024. Available at: http://naco.gov.in/sites/default/files/Paving%20the%20Way%20for%20an%20AIDS%2015122017.pdf. Accessed 24 April 2018.

Le T, Wright EJ, Smith DM, He W, Catano G, Okulicz JF, et al. Enhanced CD4+T-cell recovery with earlier HIV-1 antiretroviral therapy. New Eng J Med. 2013;368(3):218-30.

Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother‐to‐child transmission of HIV infection. Cochrane Database Systematic Rev. 2011;(7).

Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Partners in prevention hsv/hiv transmission study team. heterosexual hiv-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092-8.

Anglemyer A, Horvath T, Rutherford G. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. JAMA. 2013;310(15):1619-20.

Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532-9.

Montaner JS, Lima VD, Harrigan PR, Lourenço L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV Treatment as Prevention” experience in a Canadian setting. PloS One. 2014;9(2):e87872.

Edwards JK, Cole SR, Westreich D, Mugavero MJ, Eron JJ, Moore RD, et al. Age at entry into care, timing of antiretroviral therapy initiation, and 10-year mortality among HIV-seropositive adults in the United States. Clin Infectious Dis. 2015;61:1189-95.

Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. New Eng J Med. 2009;360(18):1815-26.

Claudia Miranda A, Moneti V, Brogueira P, Peres S, Baptista T, Aldir I, et al. Evolution trends over three decades of HIV infection late diagnosis: the experience of a Portuguese cohort of 705 HIV‐infected patients. J Inter AIDS Soc. 2014;17:19688.

Ndawinz JD, Chaix B, Koulla-Shiro S, Delaporte E, Okouda B, Abanda A, et al. Factors associated with late antiretroviral therapy initiation in Cameroon: a representative multilevel analysis. J Antimicrobial Chemotherapy. 2013;68(6):1388-99.

Celesia BM, Castronuovo D, Pinzone MR, Bellissimo F, Mughini MT, Lupo G, et al. Late presentation of HIV infection: predictors of delayed diagnosis and survival in Eastern Sicily. Eur Rev Med Pharmacol Sci. 2013;17(16):2218-24.

Gabillard D, Lewden C, Ndoye I, Moh R, Segeral O, Tonwe-Gold B, et al. Mortality, AIDS-morbidity and loss to follow-up by current CD4 cell count among HIV-1 infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration. J Acquired Immune Def Syn, 1999. 2013;62(5):555.

Gupta A, Nadkarni G, Yang WT, Chandrasekhar A, Gupte N, Bisson GP, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low-and middle-income countries (LMIC): a systematic review and meta-analysis. PloS one. 2011;6(12):e28691.

National guidelines for enumeration of CD4 2015 Available at: http://naco.gov.in/sites/default/files/CD4_Guidelines.pdf.

Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV‐infected, treatment‐naive adults. Cochrane Database Systematic Rev. 2010;(3).

Anglaret X, Scott CA, Walensky RP, Ouattara E, Losina E, Moh R, et al. Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis. Antiviral Therapy. 2013;18(1):45.

Kilaru KR, Kumar A, Sippy N. CD4 cell counts in adults with newly diagnosed HIV infection in Barbados. Revista Panamericana Salud Pública. 2004;16:302-7.

Mutimura E, Addison D, Anastos K, Hoover D, Dusingize JC, Karenzie B, et al. IeDEA Central Africa Collaboration. Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda. AIDS. 2015 Jan 2;29(1):67.

Keiser O, Anastos K, Schechter M, Balestre E, Myer L, Boulle A, et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health. 2008;13(7):870-9.

Kiertiburanakul S, Boettiger D, Lee MP, Omar SF, Tanuma J, Ng OT, et al. Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV‐positive patients. J International AIDS Soc. 2014;17(1):18804.

Siedner MJ, Ng CK, Bassett IV, Katz IT, Bangsberg DR, Tsai AC. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis. Clin Infectious Dis. 2014;60(7):1120-7.

Lahuerta M, Lima J, Nuwagaba-Biribonwoha H, Okamura M, Alvim MF, Fernandes R, et al. Factors associated with late antiretroviral therapy initiation among adults in Mozambique. PloS One. 2012;7(5):e37125.

Nash D, Wu Y, Elul B, Hoos D, El Sadr W. Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries. AIDS. 2011;25(12):1523.